Unpartnered Products: Partnerships that could be Game Changers.
By Steven Muntner, Analyst, Medtrack
14 July 2014
Take a look at our sister company Medtrack’s latest report.
As the pharmaceutical landscape continues to consolidate through acquisitions and partnerships, we examine the untapped market of unpartnered products, which represents a potential multi-billion dollar opportunity.
This analysis examines:
1. Unpartnered branded, investigational & biologic drugs by therapy area and phase
2. Private company pipelines with unpartnered products
3. Public company pipelines with low cash on hand that could hold potential for out-licensing deals
4. Recent licensing deals and royalty rates across the pharma and biotech space